Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The FACTS ARE: Undiagnosed Cardiovascular Disease Is a Killer
• 1 in 3 deaths annually are caused by heart disease
and stroke.
• 1.5 million people suffer heart attacks annually in
the U.S.
• Nearly 1/3 of the deaths could be prevented
through proactive changes in lifestyle habits.
• Often the FIRST SYMPTOM of coronary artery
disease is a heart attack.
LXGTF Management Dream Team:
https://lexingtonbiosciences.com/company/management/
LXGTF Article by Jonathan Maltz, "What is Endothelial Function..." :
https://lexingtonbiosciences.com/news/endothelial-function-important-health/
JOIN LXGTF HERE: Start your dd from LXGTF website: https://lexingtonbiosciences.com/
Great day yesterday!
Hahaha yes Italian true, good morning!
all is great, I am happy
wow, we realy need to start thinking about .50 this week
.45 breaktrough closing, wonderful
SUMMARY LXGTF : Lexington BioSciences (CSE: LNB) (OTCQB: LXGTF) is developing the HeartSentry, a new non-invasive diagnostic tool for accurately measuring and monitoring cardiovascular health.
• The HeartSentry measures the function of the endothelium – the critical inner lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the company.
• Lexington is in final stages of releasing the product into clinical studies for FDA approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general practitioners, and ultimately patients first line evaluation of cardiovascular
health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized
medicine.
What a point: Blood pressure monitor market forecast to exceed $2.6 billion by 2020
exiting...
things are here looking pretty cool
Wow we break it .45 !!!
interesting...
we are like miners looks like :)
GREAT!
“We believe that the crypto mining contracts provide some exciting opportunities for the company. We look forward to providing additional updates in the near term” Source
the news are great
Thank you for this article
STEP BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
WHY IS LXGTF better? Knowing the core health of the cardiovascular system is critical to preventing future heart attacks and strokes
• Monitoring cardiovascular health changes over time is key to prevention via lifestyle modification, physician care and ongoing monitoring.
• Traditional measures of blood pressure and cholesterol measurements are only partial indicators of cardiovascular health.
LXGTF simplify and save lifes! Current Standards are Complicated and Expensive
• Gold standard - ULTRASOUND
• Measurement directly views arterial diameter
changes
• Only at specialized diagnostic centers
• Requires trained ultrasonographer
• Expensive capital equipment needed
• Alternative method - ENDOPAT
• Measurement uses a fingertip blood oxygen
sensor and laptop computer.
• Only at specialized diagnostic centers
• Requires trained technician
Currently only used in specialized research centers by highly trained staff
I was focused on 44 and then BAAAAM
Wow moving mightly!
MUST WATCH! LXGTF video: https://vimeo.com/183611304
HeartSentry Technology rectifies this alarming situation:
Quote:
The First Sign of Cardiovascular Disease is Often an Unannounced Heart Attack!
• Current first line cardiovascular health
diagnostics are insensitive at measuring
heart disease development and
progression
• Specialized cardiovascular diagnostics
are highly invasive and expensive and
generally catch cardiovascular disease
AFTER it’s developed
we need a simple way to proactively measure and monitor
cardiovascular system health BEFORE the development of heart disease
Values
Excellence. Create a challenging and dynamic environment with excellence as an achievable goal in all we do.
Progress. Our work is focused on improving the lives of others. We believe the tools to achieve a healthy society must improve and we intend to be a positive part of this ongoing evolution.
Innovate. Consistently deliver exceptional products, identify clearly unmet needs and solve them, and always seek the potential for ever better results.
Trust. Engender trust by always performing in an ethical and professional manner.
Respect. Treat our stakeholders, investors, vendors, suppliers and future customers as we would like to be treated ourselves.
INDUSTRY WORTH BILLIONS HAVE YOU SOW IT
http://techstockinsider.com/the-wearable-tech-thats-disrupting-an-industry-worth-billions/
START YOUR DD HERE! LXGTF website: https://lexingtonbiosciences.com/
right, we want see more!
Good morning Italian! Good to see you!
great day!!!
good green begining
Power hour move
Who can disagre with you
a big step forward
HeartSentry Technology rectifies this alarming situation:
Quote:
The First Sign of Cardiovascular Disease is Often an Unannounced Heart Attack!
• Current first line cardiovascular health
diagnostics are insensitive at measuring
heart disease development and
progression
• Specialized cardiovascular diagnostics
are highly invasive and expensive and
generally catch cardiovascular disease
AFTER it’s developed
what we can see in the power hour?
this is not a hope, this will be a fact :) FDA changes everything